ProQR Therapeutics N.V. (PRQR)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Discovery and Development of Innovative, RNA Based Therapeutics	19.55M	6.59M	4.36M	2.38M	1.03M
Discovery and Development of Innovative, RNA Based Therapeutics Growth	196.41%	51.27%	83.31%	131.10%	-46.77%
Total	19.55M	6.59M	4.36M	2.38M	1.03M
Total Growth	196.41%	51.27%	83.31%	131.10%	-46.77%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Netherlands	19.55M	6.59M	4.36M	2.38M	1.03M
Netherlands Growth	196.41%	51.27%	83.31%	131.10%	-46.77%
Total	19.55M	6.59M	4.36M	2.38M	1.03M
Total Growth	196.41%	51.27%	83.31%	131.10%	-46.77%

Source: S&P Global Market Intelligence.